SCHEMBL4282686

SCHEMBL4282686

NC1=NC(N)(c2ccc(Cl)cc2)C=C(c2ccccc2Oc2ccccc2)N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPK13 O15264 1/20 0.39
GCGR P47871 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
NR1I2 O75469 3/20 0.37
HSD11B1 P28845 3/20 0.37
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
BRD4 O60885 2/20 0.35
HTR2A P28223 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A3 Q01959 1/20 0.33
PPARA Q07869 1/20 0.33
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4280081 0.78 CYP1A2 (0.37) CYP1A2MEN1KMT2ALMNADPP4
SCHEMBL4282261 0.77 HSD11B1 (0.39) HSD11B1LMNADPP4
SCHEMBL4280058 0.75 HTR2B (0.39) HTR2ALMNASMN1; SMN2
SCHEMBL4282690 0.74 MAPK13 (0.38) CYP1A2CYP3A4CYP2C9CYP2C19MAPK13
SCHEMBL4282568 0.71 ALDH1A1 (0.41) NCOA1MEN1KMT2ALMNAHPGD
SCHEMBL4291033 0.68 AGPAT2 (0.43) CYP3A4
SCHEMBL4281458 0.63 TMPRSS4 (0.34) SLC6A4SLC6A2SLC6A3MEN1KMT2A
SCHEMBL2203391 0.62 TSHR (0.58) NCOA1NCOA3BRD4SLC6A4SLC6A2
SCHEMBL15904319 0.61 CYP1A2 (0.40) CYP1A2CYP3A4CYP2C9CYP2C19MEN1
SCHEMBL6406032 0.60 NCOA1 (0.55) NCOA1NCOA3BRD4SLC6A4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT CYP1A2 4325/4885CYP3A4 4728/4885CYP2C9 4538/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT CYP1A2 4519/4885CYP3A4 4816/4885CYP2C9 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.